Celiac disease, affecting approximately 1% of the US population, is an immune-mediated response to gluten, leading to small bowel mucosa injury, villous atrophy, and subsequent malabsorption of essential nutrients. Common symptoms include diarrhea, abdominal discomfort, and bloating, while extraintestinal manifestations can include fatigue, weight loss, and osteoporosis. Key Highlights from the 2023 ACG Guidelines:
Author: Abhay Panchal
Change Healthcare is grappling with a recent cyberattack just as Medicare relief measures are coming to an end. Here are three key insights about this situation:
“Mind Your Gut,” a new book by Megan Riehl and Kate Scarlata, offers a comprehensive guide to managing irritable bowel syndrome (IBS). Here are three key insights from the book:
Dr. Jonathan Leighton offers valuable tips for handling challenging colonoscopies, providing insights to enhance procedural success and patient outcomes. Here are three key takeaways from his expert advice:
The ongoing StopUHC campaign is calling on UnitedHealthcare to reconsider its upcoming program changes affecting gastrointestinal procedures. Here are three key insights about this campaign:
The Colorectal Cancer Alliance has announced new partnerships with Blake Gastroenterology Associates, LLC, Gaudenzia Addiction Treatment & Recovery Services, and Penn Medicine. Here are three key insights about these partnerships:
Nestlé Health Science has unveiled a new GLP-1 nutrition support platform, designed to aid individuals in managing their health more effectively. Here are three key insights about this innovative platform:
ModifyHealth has announced the formation of the GI Consortium, a groundbreaking partnership aimed at supporting individuals with digestive conditions. Here are three key insights about this new initiative:
Researchers are exploring the use of lab-grown mini guts to identify the most effective treatments for Crohn’s disease, potentially revolutionizing personalized medicine. Here are three key insights about this innovative approach:
The FDA has approved Bristol Myers Squibb’s combination therapy for colorectal cancer patients with certain genetic mutations, marking a significant advancement in personalized cancer treatment. Here are three key insights about this approval: